Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human APOC3 Antibodies:
anti-Mouse (Murine) APOC3 Antibodies:
anti-Rat (Rattus) APOC3 Antibodies:
Go to our pre-filtered search.
Human Polyclonal APOC3 Primary Antibody for IHC (p), IP - ABIN153496
Wang, Song, Wagner, Pachuk, Subramanian: Development of a sensitive ELISA to quantify apolipoprotein CIII in nonhuman primate serum. in Journal of lipid research 2011
intestinal apoC-III overexpression results in the secretion of smaller, less dense chylomicron particles along with reduced triacylglycerol secretion from the intestine
Aromatic residues in the C terminus of apolipoprotein C-III mediate lipid binding and LPL (show LCP1 Antibodies) inhibition
No evidence that APOC3 3'UTR (show UTS2R Antibodies) variant SstI modulates expression of liver/intestinal miRNAs in hypertriglyceridemia.
A rare variant in APOC3(rs138326449) has been associated with triglyceride, very low-density lipoprotein, and high-density lipoprotein levels, as well as risk of coronary heart disease. Effects are unlikely to be solely predictable by the action of APOC3 through LPL (show LCP1 Antibodies).
both human APOC3 A43T heterozygotes and mice expressing human APOC3 A43T display markedly reduced circulating apoC-III levels. In mice, this reduction is due to impaired binding of A43T apoC-III to lipoproteins and accelerated renal catabolism of free apoC-III.
Gene-level meta-analysis with other studies reporting burden signals at APOC3 provides robust evidence for a replicable cardioprotective rare variant aggregation
studied the associations of apoC-III, endothelial function and diabetic peripheral neuropathy
Plasma levels of proprotein convertase subtilisin/kexin type 9 (PCSK9 (show PCSK9 Antibodies)), apolipoprotein C-III (apoC3) and small dense low density lipoprotein cholesterol (sdLDL-C) showed significant interactions with current dyslipidemias, and were predictive in the screening.
Novel sequencing techniques are detecting rare variants with larger effect sizes (eg, APOC3) , which may further improve on Cardiovascular disease risk prediction.
The APOC3 rs2070666 A allele is a risk factor for NAFLD independent of obesity, dyslipidemia, and PNPLA3 rs738409, and it might contribute to increased liver fat content in Chinese Han population.
ApoC-III inhibits turnover of TG-rich lipoproteins primarily through a hepatic clearance mechanism mediated by the LDLR (show LDLR Antibodies)/LRP1 (show LRP1 Antibodies) axis
These data strongly suggest that intestinal apoC-III is not a FoxO1 (show FOXO1 Antibodies) target and support the idea that apoC-III is not regulated coordinately with hepatic apoC-III, and establishes another key aspect of apoC-III that is unique in the intestine from the liver.
APOC3, whose dysregulation is liable for hypertriglyceridemia, is not a predisposing factor for linking overnutrition to NAFLD (show TSC2 Antibodies) in obesity
Severe hypertriglyceridaemia resulting from ApoCIII overexpression promotes restenosis and atherosclerosis
Under conditions of islet insulin (show INS Antibodies) resistance, locally produced apoCIII is an important diabetogenic factor involved in impairment of beta-cell function.
decreased ApoAI synthesis might be accounted for the lower plasma HDL (show HSD11B1 Antibodies) level in ApoCIII transgenic mice
ApoCIII hyperactivates beta cell CaV1 (show CAV1 Antibodies) channels through SR-BI (show SCARB1 Antibodies)/beta1 integrin-dependent coactivation of PKA and Src (show SRC Antibodies).
Increased plasma APOC3 concentrations predispose mice to diet-induced nonalcoholic fatty liver and hepatic insulin (show INS Antibodies) resistance.
Glucose induces apoCIII transcription, which may represent a mechanism linking hyperglycemia, hypertriglyceridemia, and cardiovascular disease in type 2 diabetes.
gene polymorphisms in APOA5 (show APOA5 Antibodies) and APOC3 are associated with meat quality traits in Kele pigs
changes in apolipoprotein A-I (show APOA1 Antibodies) and apo (show C9orf3 Antibodies) C-III mRNA were reflected in their corresponding plasma levels
apoC-I (show APOC1 Antibodies) and apoC-III inhibit lipolysis by displacing LPL (show LPL Antibodies) from lipid emulsion particles. We also propose a role for these apolipoproteins in the irreversible inactivation of LPL (show LPL Antibodies) by factors such as angptl4 (show ANGPTL4 Antibodies).
Apolipoprotein C-III is a very low density lipoprotein (VLDL) protein. APOC3 inhibits lipoprotein lipase and hepatic lipase\; it is thought to delay catabolism of triglyceride-rich particles. The APOA1, APOC3 and APOA4 genes are closely linked in both rat and human genomes. The A-I and A-IV genes are transcribed from the same strand, while the A-1 and C-III genes are convergently transcribed. An increase in apoC-III levels induces the development of hypertriglyceridemia.
, apolipoprotein C3
, apolipoprotein C-3
, apolipoprotein CIII